SELL and myeloid sarcoma: A recent study demonstrated that the proportion of CD4+ T-cells expressing L-selectin was lower in long-term NTZ-treated patients than in untreated MS patients or healthy controls, and an unusually low percentage of CD4+ T-cells expressing CD62L was associated with a higher risk of developing PML (59).